ADRB1 and angiosarcoma: To determine if a similar outcome could be observed in angiosarcoma models, we evaluated the viability of two angiosarcoma cell lines following treatment with propranolol, β1-AR selective antagonists (esmolol and atenolol), or β2-AR selective antagonists (butoxamine and ICI-118,551).